Uveal Melanoma Webinar: Part II — Navigating Treatment in the Metastatic Setting
Published:
04/02/2026
Categories:
Presented in partnership with Save Your Skin Foundation and Ocumel Canada
Ocumel Canada (OC), is powered by Save Your Skin Foundation, was formed to increase awareness, advance treatment options, and build a supportive community for those diagnosed with primary and/or metastatic ocular melanoma (OM).
April 30 | 7:00–7:30 PM ET
Held virtually via Zoom (register below)
Join us for Part II of our uveal melanoma webinar series, focused on understanding treatment options and decision-making in the metastatic setting.
In this webinar, a panel of leading melanoma experts will walk through how care is approached today. Together, they will discuss how doctors choose between available therapies such as tebentafusp, liver-directed treatments, and emerging targeted options. The conversation will also explore how treatments may be sequenced over time, when combination approaches may be considered, and how new tools like blood-based monitoring (ctDNA) may help guide decisions.
The panel will also share updates on promising therapies currently in development, offering insight into what may be on the horizon for patients living with metastatic uveal melanoma.
This discussion is designed to help patients and caregivers better understand the evolving treatment landscape, ask informed questions, and feel more confident navigating care.
The webinar will conclude with a live Q&A.
Moderator
Shaheer Ahmad Khan, DO
Dr. Khan is an attending oncologist at R.J. Zuckerberg Cancer Hospital and Lenox Hill Hospital, and an assistant professor at the Zucker School of Medicine at Hofstra/Northwell. He specializes in melanoma and other cancers, with a focus on advancing treatment options for patients.
Guest Speakers
Marcus Butler, MD
Dr. Butler is a medical oncologist at Princess Margaret Cancer Centre in Toronto and Assistant Professor at the University of Toronto. He leads melanoma and skin oncology efforts and is deeply involved in immunotherapy research, including how treatments affect the immune system. His work focuses on developing new therapies and advancing clinical trials for melanoma.
Richard D. Carvajal, MD
Dr. Carvajal is Deputy Physician-in-Chief and Director of Medical Oncology at Northwell Health Cancer Institute and an internationally recognized leader in melanoma research and early drug development. His work centers on developing innovative therapies with the goal of improving outcomes for patients with melanoma and other cancers.
Jose Lutzky, MD
Dr. Lutzky is Director of Cutaneous Oncology Services and Director of the Clinical Trials Coordinating Unit at Sylvester Comprehensive Cancer Center, where he serves as a professor of medicine. A triple board-certified hematologist and oncologist, he specializes in melanoma and brings extensive experience in clinical research and patient care.
Recent Posts
Apr. 02, 2026
Uveal Melanoma Webinar: Part II — Navigating Treatment in the Metastatic Setting
Mar. 26, 2026
Wade Watson, Stage III Melanoma Survivor
Mar. 03, 2026
Cancer is More Than a Diagnosis: Mind, Meaning, and Healing
Feb. 19, 2026
Merlin CP-GEP Becomes the First and Only Gene Expression Profile Test Recommended by NCCN®
Feb. 05, 2026